ANGO - Medical Devices Player AngioDynamics Exceeds Q1 Expectations Sticks To Annual Guidance | Benzinga
AngioDynamics Inc (NASDAQ: ANGO) has reported a Q1 FY24 adjusted EPS loss of $(0.12), beating the consensus of $(0.13) but higher than $(0.06) reported a year ago.
Q1 sales decreased 3.5% Y/Y to $78.68 million, beating the analyst consensus of $77.69 million.
On a pro forma basis, excluding sales of Dialysis and BioSentry, net sales increased 5.7% Y/Y.
Med Tech net sales were $26.5 million, up 13.3% Y/Y, driven by ...